A novel thromboxane synthetase inhibitor, DP-1904, inhibits human blood eosinophil degranulation

Devendra K. Agrawal, Mitsutaka Takami, Shin Etsu Ono

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Eosinophils have been recognized to be associated with various immune responses and disease processes including bronchial asthma. Eosinophils release a number of cytotoxic and neurotoxic mediators. However, the factors regulating such release and the underlying mechanisms are unclear. In this study, we investigated the effect of a selective and potent thromboxane synthase inhibitor, DP-1904, on the release of eosinophil cationic protein (ECP) in platelet activating factor (PAF) and IgG-stimulated human blood eosinophils. PAF (1 μM) and IgG both released ECP which constituted about 25-30% of the total ECP content. The control protein, ovalbumin, did not release any ECP over the basal values. DP-1904 in two different concentrations, 10 μM and 100 μM, significantly attenuated the release of ECP in response to PAF or IgG. The mean percent inhibition by 10 μM DP-1904 was 49 ± 10 and 31 ± 2 against PAF and IgG-induced ECP release, respectively. However, at 100 μM DP-1904 the percent inhibition was 76 ± 14 and 67 ± 2, respectively. These data suggest that TXA2 is an important mediator in the regulation of eosinophil degranulation, and DP-1904 thus might prove beneficial in the treatment of bronchial asthma.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalInflammation
Volume21
Issue number1
DOIs
StatePublished - 1997

Fingerprint

Thromboxane-A Synthase
Eosinophil Cationic Protein
Eosinophils
Platelet Activating Factor
Immunoglobulin G
Asthma
Thromboxanes
Immune System Diseases
Ovalbumin
nafagrel

All Science Journal Classification (ASJC) codes

  • Cell Biology
  • Immunology
  • Medicine(all)

Cite this

A novel thromboxane synthetase inhibitor, DP-1904, inhibits human blood eosinophil degranulation. / Agrawal, Devendra K.; Takami, Mitsutaka; Ono, Shin Etsu.

In: Inflammation, Vol. 21, No. 1, 1997, p. 1-8.

Research output: Contribution to journalArticle

@article{ec3245951bf142408ffb9c7bbddfea52,
title = "A novel thromboxane synthetase inhibitor, DP-1904, inhibits human blood eosinophil degranulation",
abstract = "Eosinophils have been recognized to be associated with various immune responses and disease processes including bronchial asthma. Eosinophils release a number of cytotoxic and neurotoxic mediators. However, the factors regulating such release and the underlying mechanisms are unclear. In this study, we investigated the effect of a selective and potent thromboxane synthase inhibitor, DP-1904, on the release of eosinophil cationic protein (ECP) in platelet activating factor (PAF) and IgG-stimulated human blood eosinophils. PAF (1 μM) and IgG both released ECP which constituted about 25-30{\%} of the total ECP content. The control protein, ovalbumin, did not release any ECP over the basal values. DP-1904 in two different concentrations, 10 μM and 100 μM, significantly attenuated the release of ECP in response to PAF or IgG. The mean percent inhibition by 10 μM DP-1904 was 49 ± 10 and 31 ± 2 against PAF and IgG-induced ECP release, respectively. However, at 100 μM DP-1904 the percent inhibition was 76 ± 14 and 67 ± 2, respectively. These data suggest that TXA2 is an important mediator in the regulation of eosinophil degranulation, and DP-1904 thus might prove beneficial in the treatment of bronchial asthma.",
author = "Agrawal, {Devendra K.} and Mitsutaka Takami and Ono, {Shin Etsu}",
year = "1997",
doi = "10.1023/A:1027330506697",
language = "English",
volume = "21",
pages = "1--8",
journal = "Inflammation",
issn = "0360-3997",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - A novel thromboxane synthetase inhibitor, DP-1904, inhibits human blood eosinophil degranulation

AU - Agrawal, Devendra K.

AU - Takami, Mitsutaka

AU - Ono, Shin Etsu

PY - 1997

Y1 - 1997

N2 - Eosinophils have been recognized to be associated with various immune responses and disease processes including bronchial asthma. Eosinophils release a number of cytotoxic and neurotoxic mediators. However, the factors regulating such release and the underlying mechanisms are unclear. In this study, we investigated the effect of a selective and potent thromboxane synthase inhibitor, DP-1904, on the release of eosinophil cationic protein (ECP) in platelet activating factor (PAF) and IgG-stimulated human blood eosinophils. PAF (1 μM) and IgG both released ECP which constituted about 25-30% of the total ECP content. The control protein, ovalbumin, did not release any ECP over the basal values. DP-1904 in two different concentrations, 10 μM and 100 μM, significantly attenuated the release of ECP in response to PAF or IgG. The mean percent inhibition by 10 μM DP-1904 was 49 ± 10 and 31 ± 2 against PAF and IgG-induced ECP release, respectively. However, at 100 μM DP-1904 the percent inhibition was 76 ± 14 and 67 ± 2, respectively. These data suggest that TXA2 is an important mediator in the regulation of eosinophil degranulation, and DP-1904 thus might prove beneficial in the treatment of bronchial asthma.

AB - Eosinophils have been recognized to be associated with various immune responses and disease processes including bronchial asthma. Eosinophils release a number of cytotoxic and neurotoxic mediators. However, the factors regulating such release and the underlying mechanisms are unclear. In this study, we investigated the effect of a selective and potent thromboxane synthase inhibitor, DP-1904, on the release of eosinophil cationic protein (ECP) in platelet activating factor (PAF) and IgG-stimulated human blood eosinophils. PAF (1 μM) and IgG both released ECP which constituted about 25-30% of the total ECP content. The control protein, ovalbumin, did not release any ECP over the basal values. DP-1904 in two different concentrations, 10 μM and 100 μM, significantly attenuated the release of ECP in response to PAF or IgG. The mean percent inhibition by 10 μM DP-1904 was 49 ± 10 and 31 ± 2 against PAF and IgG-induced ECP release, respectively. However, at 100 μM DP-1904 the percent inhibition was 76 ± 14 and 67 ± 2, respectively. These data suggest that TXA2 is an important mediator in the regulation of eosinophil degranulation, and DP-1904 thus might prove beneficial in the treatment of bronchial asthma.

UR - http://www.scopus.com/inward/record.url?scp=0031010685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031010685&partnerID=8YFLogxK

U2 - 10.1023/A:1027330506697

DO - 10.1023/A:1027330506697

M3 - Article

VL - 21

SP - 1

EP - 8

JO - Inflammation

JF - Inflammation

SN - 0360-3997

IS - 1

ER -